1. Home
  2. EHTH vs GANX Comparison

EHTH vs GANX Comparison

Compare EHTH & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo eHealth Inc.

EHTH

eHealth Inc.

HOLD

Current Price

$4.33

Market Cap

105.1M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$4.04

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHTH
GANX
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.1M
159.2M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
EHTH
GANX
Price
$4.33
$4.04
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.67
$8.00
AVG Volume (30 Days)
263.5K
1.2M
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$542,951,000.00
N/A
Revenue This Year
$4.92
N/A
Revenue Next Year
$0.24
N/A
P/E Ratio
$100.55
N/A
Revenue Growth
16.79
N/A
52 Week Low
$3.18
$1.41
52 Week High
$11.36
$4.34

Technical Indicators

Market Signals
Indicator
EHTH
GANX
Relative Strength Index (RSI) 54.99 70.23
Support Level $3.64 $3.94
Resistance Level $4.56 $4.34
Average True Range (ATR) 0.26 0.38
MACD 0.08 0.04
Stochastic Oscillator 75.39 79.01

Price Performance

Historical Comparison
EHTH
GANX

About EHTH eHealth Inc.

eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: